HopeStage
Back to all studies
TerminatedNCT00288353

Estimating and Reducing the Cardiovascular Risk of Patients With Schizophrenia Drugs From Lipid Measures and Ischemic Electrocardiographic Changes

Medication studyAges 18–65United States
The study in practice

Understand this study

Who could participate?

Listed age limits: 18 years to 65 years.

Listed locations
NashvilleSee all locations and recruitment
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.

Get this study by email

HopeStage may email me about this study.
Loading the security check...

What to know before participating

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Things to check before joining

Study start dateJanuary 2006
Recruitment status
Terminated
Enrollment listed in the registry
48
Sponsor
Northwestern University
Sponsor type
University
Study type
Drug
Intervention type
Drug
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
United States
Age range
From 18 Years to 65 Years
Official registry ID
NCT00288353
Official title
Show the full official title

Estimating and Reducing the Cardiovascular Risk of Patients With Schizophrenia Drugs From Lipid Measures and Ischemic Electrocardiographic Changes

Recruitment & locations

Terminated

Nashville

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Northwestern University, a university.

Does this study involve medication?

Yes. The study involves medication, including aripiprazole (Abilify) and ziprasidone (Geodon).

Who can participate?

Listed age limits: 18 years to 65 years.

Is this study still recruiting?

The registry lists this study as terminated.

Want to explore more studies?

Explore studies